Methods and Results: A total of 130 patients from 3 sites with le

Methods and Results: A total of 130 patients from 3 sites with left ventricular ejection fraction ARN-509 Endocrinology & Hormones inhibitor <= 35% were enrolled during hospitalization for heart failure (HF) and randomly assigned to therapy guided by BNP and clinical assessment (BNP strategy) or clinical assessment alone. The clinical goal was resolution of congestion without hypotension or renal dysfunction. In the BNP arm, therapy was adjusted to achieve optimal fluid status, defined as the BNP level and congestion score obtained at the time of discharge. In

the clinical assessment arm, therapy was titrated to achieve optimal fluid status, represented by the patient’s signs and symptoms at the time of discharge. Exclusion criteria were serum creatinine >3.5 mg/dL and acute coronary syndrome. Follow-up was done in HF clinics. BNP was measured with the use of a rapid assay test. There was no significant difference in number of days alive and not hospitalized

(hazard ratio 0.72, 95% confidence interval 0.41-1.27; P = .25), change in serum creatinine, or change in systolic blood pressure (SBP). BNP strategy was associated with a trend toward a lower blood urea nitrogen (24 mg/dL vs 29 mg/dL; P = .07); BNP strategy patients received significantly more angiotensin converting enzyme (ACE) inhibitors, beta-blockers, and the combination of ACE inhibitor or angiotensin receptor blocker plus beta-blockers.

Conclusions: learn more BNP strategy was not associated with more days alive and not hospitalized, but the strategy appeared to be safe and was associated with increased use of evidence-based medications. (J Cardiac Fail 2011;17:613-621)”
“Magnetic

properties, phase constitution, and microstructure of melt spun R-lean and B-enriched Mischmetal (MM)-Fe-Co-Ti-B nanocomposites have been investigated. The thermal magnetic analysis show that only 2:14:1 and alpha-Fe [alpha-(Fe, Co)] phases appear for MM(A)(9.5)Fe(78.5)Ti(2)B(10) and MM(A)(9)Fe(79.5)Co(2.5)Ti(1)B(8) Adavosertib ribbons, while an additional Fe(3)B phase is present for R(9.25)Fe(79.25)Co(2.5)Ti(1)B(8) [R=MM(A), MM(B), and MM(C)] ribbons. The magnetic properties of the above nanocomposites are determined not only by the phase constitution of MM-Fe-Co-Ti-B nanocomposites but also by the composition of MMs. Besides, fine grain size of 15-40 nm is almost unchanged for the ribbons with various MMs, giving rise to the strong exchange coupling effect between magnetic grains and the improved magnetic performance. In this study, the optimum magnetic properties of B(r) = 9.6 kG, (i)H(c)= 8.6 kOe, and (BH)(max) = 18.2 MG Oe can be achieved for MM(B)(9.25)Fe(79.25)Co(2.5)Ti(1)B(8) nanocomposites. (C) 2009 American Institute of Physics. [DOI: 10.1063/1.

Comments are closed.